Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)
November 10th, 2009 Posted by: admin
Purpose: To perform a prospective study on central retinal vein occlusion (CRVO) to evaluate whether visual acuity can be improved and macular oedema reduced in response to intravitreal injections of bevacizumab.Methods: The case material comprised 13 patients (aged 34[ndash]79 years), duration of CRVO was 2 weeks to 6 months, baseline ETDRS visual acuity 0.06[ndash]0.4 (mean Snellen 0.13, derived from logMAR value) and intraocular pressure (IOP) 12[ndash]20 (mean 15.2) mmHg. Clinical examination, including optical coherence tomography (OCT), was carried out at baseline and every 6 weeks, digital fluorescein angiography at baseline, at 3 months and 6 months. Intravitreal injections of bevacizumab (1.25 mg) were given under microscopic control at baseline and every 6 weeks during the 6-m
